Skip to main content

Eosinophilic Esophagitis

17
Pipeline Programs
21
Companies
32
Clinical Trials
5 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
4
0
8
1
3
1
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
788%
Small Molecule
113%
+ 30 programs with unclassified modality

Competitive Landscape

21 companies ranked by most advanced pipeline stage

Colorado Therapeutics
Colorado TherapeuticsCO - Louisville
7 programs
1
1
Omeprazole 20mg BIDPhase 41 trial
DupilumabPhase 2Monoclonal Antibody1 trial
Cortisol levelN/A1 trial
Esophageal String TestN/A1 trial
Esophageal String TestN/A1 trial
+2 more programs
Active Trials
NCT05246085Unknown300Est. Jul 2023
NCT03305653Completed21Est. Mar 2019
NCT03803527Withdrawn0Est. Aug 2021
+4 more trials
Dr. Falk Pharma
Dr. Falk PharmaGermany - Freiburg
5 programs
2
3
BudesonidePhase 31 trial
Budesonide 0.5mg orodispersible tablet twice dailyPhase 31 trial
Budesonide 1mg orodispersible tablet twice dailyPhase 31 trial
Mesalamine Oral ProductPhase 21 trial
low dose budesonide tabletPhase 21 trial
Active Trials
NCT05488405Completed5Est. Jul 2023
NCT02280616Completed76Est. May 2014
NCT06596252Recruiting308Est. Mar 2027
+2 more trials
AstraZeneca
AstraZenecaCAMBRIDGE, United Kingdom
2 programs
1
EsomeprazolePhase 2/3Small Molecule1 trial
inhaled/swallowed budesonideN/A1 trial
Active Trials
NCT00961233Completed25Est. Nov 2011
NCT00728481Completed51Est. Dec 2010
CSL Seqirus
CSL SeqirusUK - Maidenhead
1 program
1
Alpha-proteinase inhibitorPhase 2
EMS
EMSBrazil - Hortolândia
1 program
1
Florence 30 μg/mLPhase 21 trial
Active Trials
NCT02873468Unknown116Est. Nov 2025
BioTherapeutics Inc
BioTherapeutics IncVA - Blacksburg
1 program
1
IRL201104Phase 21 trial
Active Trials
NCT05084963Completed36Est. Oct 2022
Sandoz
SandozAustria - Kundl
1 program
1
QAX576 placeboPhase 21 trial
Active Trials
NCT01022970Completed25
DBV Technologies
DBV TechnologiesFrance - Châtillon
1 program
1
Viaskin Milk 500 mcgPhase 21 trial
Active Trials
NCT02579876Completed20Est. Nov 2018
Aqilion
AqilionSweden - Helsingborg
1 program
1
AQ280Phase 12 trials
Active Trials
NCT07093008Completed9Est. Jul 2025
NCT05485779Completed66Est. Jul 2023
NImmune Biopharma
NImmune BiopharmaVA - Blacksburg
1 program
1
BT-11 lowPhase 11 trial
Active Trials
NCT04835168Withdrawn0Est. Jun 2022
MSD
MSDIreland - Ballydine
1 program
1
Montelukast/ SingulairPhase 11 trial
Active Trials
NCT00511316Completed41Est. Sep 2015
Sharp Therapeutics
Sharp TherapeuticsPA - Pittsburgh
1 program
1
Montelukast/ SingulairPhase 1
Allergy Therapeutics
Allergy TherapeuticsUK - West Sussex
4 programs
CEGIR 7807: Validation of Online Cohort of EGID Patients Enrolled in RDCRN CEGIR Contact RegistryN/A1 trial
Characteristics and Inflammatory Markers in Children with Eosinophilic Esophagitis (EoE)N/A1 trial
Characteristics of Eosinophilic Gastritis, Enteritis, and Colitis in a Multi-Site CohortN/A1 trial
Transnasal esophagoscopyN/A1 trial
Active Trials
NCT03382678Completed187Est. Jul 2020
NCT03980886Recruiting1,500Est. Dec 2028
NCT02897271Completed381Est. May 2020
+1 more trials
Regeneron
RegeneronTARRYTOWN, NY
4 programs
DupilumabN/AMonoclonal Antibody
DupilumabPHASE_2Monoclonal Antibody
DupilumabPHASE_3Monoclonal Antibody
Eosinophilic EsophagitisPHASE_4
CSL Behring
CSL BehringIL - Bradley
1 program
Alpha-proteinase inhibitorPHASE_21 trial
Active Trials
NCT05485155Recruiting15Est. Jan 2027
Revolo Biotherapeutics
1 program
IRL201104PHASE_2
Phathom Pharmaceuticals
Phathom PharmaceuticalsFLORHAM PARK, NJ
1 program
VonoprazanPHASE_21 trial
Active Trials
NCT06851559Recruiting80Est. Mar 2027
Celldex Therapeutics
1 program
barzolvolimabPHASE_2Monoclonal Antibody1 trial
Active Trials
NCT05774184Completed86Est. Jan 2026
Bristol Myers Squibb
1 program
CC-93538PHASE_31 trial
Active Trials
NCT04991935Completed367Est. Aug 2025
Sanofi
SanofiPARIS, France
1 program
DupilumabPHASE_3Monoclonal Antibody1 trial
Active Trials
NCT03633617Completed321Est. Jun 2022
Teva
TevaIsrael - Petach Tikva
1 program
reslizumabPHASE_3Monoclonal Antibody1 trial
Active Trials
NCT00635089Completed190Est. Jan 2012

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
Colorado TherapeuticsOmeprazole 20mg BID
Bristol Myers SquibbCC-93538
Dr. Falk PharmaBudesonide
SanofiDupilumab
Dr. Falk PharmaBudesonide 0.5mg orodispersible tablet twice daily
Dr. Falk PharmaBudesonide 1mg orodispersible tablet twice daily
Tevareslizumab
AstraZenecaEsomeprazole
Phathom PharmaceuticalsVonoprazan
CSL BehringAlpha-proteinase inhibitor
Colorado TherapeuticsDupilumab
Celldex Therapeuticsbarzolvolimab
Dr. Falk PharmaMesalamine Oral Product
BioTherapeutics IncIRL201104
EMSFlorence 30 μg/mL

Showing 15 of 32 trials with date data

Clinical Trials (32)

Total enrollment: 5,375 patients across 32 trials

Proton Pump Inhibitor (PPI) Response in Eosinophilic Esophagitis Assessed by Transnasal Endoscopy (TNE)

Start: Oct 2020Est. completion: Aug 202490 patients
Phase 4Active Not Recruiting

Safety Study of CC-93538 in Adult and Adolescent Participants With Eosinophilic Esophagitis

Start: Aug 2022Est. completion: Aug 2025367 patients
Phase 3Completed

Once Daily Versus Twice Daily Budesonide Orodispersible Tablets for Induction of Remission in EoE

Start: May 2021Est. completion: Mar 2027308 patients
Phase 3Recruiting

Study to Determine the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Eosinophilic Esophagitis (EoE)

Start: Sep 2018Est. completion: Jun 2022321 patients
Phase 3Completed
NCT02493335Dr. Falk PharmaBudesonide 0.5mg orodispersible tablet twice daily

Maintenance of Remission With Budesonide Orodispersible Tablets vs. Placebo in Eosinophilic Esophagitis

Start: Jan 2016Est. completion: Dec 2020204 patients
Phase 3Completed
NCT02434029Dr. Falk PharmaBudesonide 1mg orodispersible tablet twice daily

Budesonide Orodispersible Tablet vs. Placebo in Active Eosinophilic Esophagitis

Start: Nov 2015Est. completion: Oct 201688 patients
Phase 3Completed
NCT00635089Tevareslizumab

Open-Label Extension Study of Reslizumab in Pediatric Subjects With Eosinophilic Esophagitis

Start: Jul 2008Est. completion: Jan 2012190 patients
Phase 3Completed

The Role Of Gastroesophageal Reflux Disease (GERD) in Eosinophilic Esophagitis

Start: May 2008Est. completion: Dec 201051 patients
Phase 2/3Completed

A Study in Adult Participants With EoE to Evaluate Vonoprazan 20 mg Compared to Placebo After 12 Weeks and to Evaluate Vonoprazan 20 mg Up to 24 Weeks

Start: Oct 2025Est. completion: Mar 202780 patients
Phase 2Recruiting
NCT05485155CSL BehringAlpha-proteinase inhibitor

Zemaira Eosinophilic Esophagitis Pilot Study

Start: May 2025Est. completion: Jan 202715 patients
Phase 2Recruiting

Dupilumab Versus Topical Corticosteroid Effectiveness - Comparison in the Treatment of Stenotic EoE

Start: Dec 2024Est. completion: Mar 202772 patients
Phase 2Recruiting

A Study of CDX-0159 in Patients With Eosinophilic Esophagitis

Start: Jun 2023Est. completion: Jan 202686 patients
Phase 2Completed
NCT05488405Dr. Falk PharmaMesalamine Oral Product

Mesalazine Oral Suspension in Active Eosinophilic Esophagitis

Start: Feb 2023Est. completion: Jul 20235 patients
Phase 2Completed

A Study to Assess the Efficacy, Safety and Tolerability of IRL201104 in Adults With Active Eosinophilic Esophagitis

Start: Oct 2021Est. completion: Oct 202236 patients
Phase 2Completed
NCT02873468EMSFlorence 30 μg/mL

Efficacy and Safety of Three Doses of Florence Oral Suspension in Adults With Eosinophilic Esophagitis

Start: Apr 2021Est. completion: Nov 2025116 patients
Phase 2Unknown
NCT02579876DBV TechnologiesViaskin Milk 500 mcg

Milk Patch for Eosinophilic Esophagitis

Start: Oct 2015Est. completion: Nov 201820 patients
Phase 2Completed
NCT02280616Dr. Falk Pharmalow dose budesonide tablet

Budesonide Effervescent Tablets vs. Viscous Budesonide Suspension vs. Placebo in Eosinophilic Esophagitis

Start: Jun 2011Est. completion: May 201476 patients
Phase 2Completed
NCT01022970SandozQAX576 placebo

Efficacy and Safety of QAX576 in Patients With Eosinophilic Esophagitis

Start: Nov 200925 patients
Phase 2Completed

Comparing the Extent to Which AQ280 is Made Available in the Body After Single Oral Doses of a Capsule Formulation Versus a Tablet for Oral Suspension Formulation

Start: Jun 2025Est. completion: Jul 20259 patients
Phase 1Completed

SAD, MAD and Food Effect Evaluation of Safety, Tolerability, and PK of AQ280 in Healthy Subjects

Start: Jul 2022Est. completion: Jul 202366 patients
Phase 1Completed

Safety and Pharmacokinetics of Orodispersible BT-11 in Active Eosinophilic Esophagitis

Start: Jan 2022Est. completion: Jun 20220
Phase 1Withdrawn
NCT00511316MSDMontelukast/ Singulair

Trial of Montelukast in Eosinophilic Esophagitis

Start: Aug 2007Est. completion: Sep 201541 patients
Phase 1Completed

Evaluating Adrenal Insufficiency in Adults With Eosinophilic Esophagitis on Chronic Swallowed Topical Steroids

Start: Aug 2022Est. completion: Jul 2023300 patients
N/AUnknown
NCT03803527Colorado TherapeuticsEsophageal String Test

Metabolomic Profiling of Eosinophilic Esophagitis

Start: Dec 2019Est. completion: Aug 20210
N/AWithdrawn
NCT03980886Allergy TherapeuticsCharacteristics and Inflammatory Markers in Children with Eosinophilic Esophagitis (EoE)

Characteristics and Inflammatory Markers in Children with Eosinophilic Esophagitis (EoE)

Start: Feb 2019Est. completion: Dec 20281,500 patients
N/ARecruiting
NCT03382678Allergy TherapeuticsCEGIR 7807: Validation of Online Cohort of EGID Patients Enrolled in RDCRN CEGIR Contact Registry

CEGIR 7807: Validation of Online Cohort of EGID Patients Enrolled in RDCRN CEGIR Contact Registry

Start: Sep 2018Est. completion: Jul 2020187 patients
N/ACompleted
NCT03305653Colorado TherapeuticsEsophageal String Test

Use of Esophageal String Test to Understand Symptoms, Inflammation, and Function in Eosinophilic Esophagitis

Start: May 2018Est. completion: Mar 201921 patients
N/ACompleted
NCT03342391Allergy TherapeuticsTransnasal esophagoscopy

CEGIR 7808: Use of Unsedated Transnasal Esophagoscopy (TNE) to Monitor Dietary Management of Eosinophilic Esophagitis in Children

Start: Oct 2017Est. completion: Sep 20205 patients
N/ACompleted
NCT02897271Allergy TherapeuticsCharacteristics of Eosinophilic Gastritis, Enteritis, and Colitis in a Multi-Site Cohort

Characteristics of Eosinophilic Gastritis, Enteritis, and Colitis in a Multi-Site Cohort

Start: Aug 2016Est. completion: May 2020381 patients
N/ACompleted
NCT02453126Colorado TherapeuticsFibrostenotic Eosinophilic Esophagitis: Assessment Tools

Fibrostenotic Eosinophilic Esophagitis: Assessment Tools

Start: Dec 2014Est. completion: Jun 2024250 patients
N/AUnknown
NCT00961233AstraZenecainhaled/swallowed budesonide

Topical Budesonide Treatment for Eosinophilic Esophagitis (EoE)

Start: Oct 2009Est. completion: Nov 201125 patients
N/ACompleted
NCT02008903Colorado TherapeuticsEsophageal String Test in Eosinophilic Esophagitis

Esophageal String Test in Eosinophilic Esophagitis

Start: Jan 2009Est. completion: Jan 2025440 patients
N/AUnknown

Related Jobs

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

3 late-stage (Phase 3) programs, potential near-term approvals
5 actively recruiting trials targeting 5,375 patients
21 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.